
Opinion|Videos|December 16, 2024
Demographics and Baseline Characteristics Across Spesolimab Dose Groups
Key Takeaways
Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5

















